Delivering new horizons for heart health

Beyond statins

Esperion is a pharmaceutical company focused on developing and commercializing first-in-class, oral therapies for low-density, lipoprotein cholesterol (LDL-C) lowering for the treatment of patients with hypercholesterolemia.

Many patients with elevated risk of heart disease are unable to benefit from statins, the current leading treatments, due to the side effects caused by these therapies: this is known as statin intolerance. Our lead product candidate, ETC-1002 (bempedoic acid), is a first-in-class, orally available, small molecule designed to significantly lower elevated levels of LDL-C — without the muscle-related side effects associated with statin use.

Clinical Studies

Esperion announced positive top-line results from ETC-1002-014, a Phase 2 exploratory safety study evaluating the efficacy and safety of ETC-1002 (bempedoic acid) monotherapy vs. placebo in 143 patients with both hypercholesterolemia and hypertension. Learn more about our clinical study results.


Meet Esperion

Our founder and chief scientific officer, Roger Newton, co-discovered the statin marketed as Lipitor® — the most commonly prescribed LDL-C lowering therapy in the world and best-selling drug in the pharmaceutical industry’s history. Learn more about our management team’s track record of success.


Statin Intolerance

Despite the known efficacy of statins, approximately 5-20% of adults who experience muscle pain or weakness discontinue statin therapy because of muscle related adverse events: this is known as statin intolerance.